Home Medizin Biosimilars haben die Kosten von Infliximab gesenkt

Biosimilars haben die Kosten von Infliximab gesenkt

von NFI Redaktion

In Las Vegas, two new retrospective analyses examined the introduction of biosimilars and their impact on the cost and access to original biologics for private insurers and Medicare patients. The studies were presented at the annual Crohn’s and Colitis Congress, a partnership of the Crohn’s & Colitis Foundation and the American Gastroenterological Association.

According to Dr. Sara Horst, an associate professor of Gastroenterology, Hepatology, and Nutrition at Vanderbilt University Medical Center in Nashville, Tennessee, the increase in the use of biosimilars among Medicare patients in the U.S. since their introduction indicates a growing comfort among clinicians regarding their clinical practice use. This is particularly important for the older population, Dr. Horst noted during a poster presentation session at the congress.

One study focused on Medicare Part D participants and observed trends in infliximab prescriptions between 2013 and 2021, taking into account the introduction of biosimilars in 2017. The study found a significant decrease in infliximab costs and claims after the introduction of biosimilars. The researchers highlighted the need for further examination of state-specific trends to ensure equitable access across all regions.

Another study, using data from the Merative Marketscan Commercial Claims and Encounters Database, analyzed the use of infliximab and its biosimilar from 2015 to 2021. The study revealed a substantial decrease in the cost of infliximab per vial after the introduction of biosimilars, potentially improving access to these medications for patients with inflammatory bowel disease (IBD).

Dr. Horst emphasized the importance of assessing whether these cost savings translated into patient savings, a concern echoed by Dr. David T. Rubin of the University of Chicago. While the introduction of biosimilars has led to cost reductions for insurers and health organizations, it remains unclear if patients have directly benefited from these savings.

Despite these limitations, Dr. Rubin welcomed the connection between the introduction of biosimilars and the decreasing costs of the original product (Remicade). He noted that while these changes have not necessarily resulted in lower costs for patients or improved access, it is promising to see the impact of biosimilars on cost reduction.

Overall, the studies underscore the evolving landscape of biosimilar use in the U.S. and the need for continued research to ensure equitable access and affordability for patients. Results from these analyses offer valuable insights into the potential impact of biosimilars on the healthcare landscape.

Dr. Paglinco and Mr. Goldman have no relevant financial disclosures. Dr. Horst has advised Janssen, Takeda, Bristol-Myers Squibb, and Abbvie. Dr. Rubin has received grants from Takeda and has served as a consultant for Abbvie, Bristol-Myers Squibb, Janssen Pharmaceuticals, Lilly, Pfizer, and Takeda.

This article originally appeared on MDedge.com as part of the Medscape Professional Network.

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.